Cabot Wellington LLC lowered its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 3.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 147,903 shares of the biopharmaceutical company’s stock after selling 5,100 shares during the period. Gilead Sciences makes up about 10.3% of Cabot Wellington LLC’s investment portfolio, making the stock its 3rd largest position. Cabot Wellington LLC’s holdings in Gilead Sciences were worth $11,794,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Lawson Kroeker Investment Management Inc. NE acquired a new position in shares of Gilead Sciences during the first quarter valued at about $6,835,000. Franklin Street Advisors Inc. NC boosted its position in shares of Gilead Sciences by 6.2% in the first quarter. Franklin Street Advisors Inc. NC now owns 217,411 shares of the biopharmaceutical company’s stock valued at $19,971,000 after buying an additional 12,758 shares during the last quarter. Capital Asset Advisory Services LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at about $1,690,000. Banced Corp boosted its position in shares of Gilead Sciences by 20.5% in the first quarter. Banced Corp now owns 15,179 shares of the biopharmaceutical company’s stock valued at $1,395,000 after buying an additional 2,583 shares during the last quarter. Finally, Webster Bank N. A. boosted its position in shares of Gilead Sciences by 6.8% in the first quarter. Webster Bank N. A. now owns 26,811 shares of the biopharmaceutical company’s stock valued at $2,463,000 after buying an additional 1,707 shares during the last quarter. Institutional investors own 77.94% of the company’s stock.
Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.916% during midday trading on Monday, reaching $80.625. 4,455,953 shares of the company were exchanged. The company has a market capitalization of $106.40 billion, a price-to-earnings ratio of 7.076 and a beta of 1.06. The company has a 50 day moving average of $79.46 and a 200-day moving average of $85.89. Gilead Sciences Inc. has a 52-week low of $76.67 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.15 earnings per share. On average, equities research analysts anticipate that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.31%. The ex-dividend date of this dividend is Wednesday, September 14th. Gilead Sciences’s payout ratio is 16.56%.
Several research analysts have issued reports on GILD shares. Morgan Stanley reiterated a “hold” rating on shares of Gilead Sciences in a report on Sunday, May 29th. Citigroup Inc. reissued a “buy” rating and set a $105.00 price target on shares of Gilead Sciences in a research report on Tuesday, May 31st. Gabelli began coverage on shares of Gilead Sciences in a research report on Wednesday, June 1st. They set a “buy” rating and a $109.00 price target for the company. Robert W. Baird reissued an “outperform” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Monday, June 6th. Finally, Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, June 8th. Nine analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $105.26.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total value of $9,444,960.00. Following the completion of the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider John F. Milligan sold 70,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total value of $5,441,800.00. Following the completion of the sale, the insider now owns 1,128,963 shares of the company’s stock, valued at approximately $87,765,583.62. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.